S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities
S&P 500   3,852.36
DOW   32,920.46
QQQ   311.72
Retirement Plans in 2023: Choosing the Right Account
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Mullen Automotive Stock Gains Momentum On Positive News
Apple’s Earnings, Expectations and Surprises
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Cathie Woods' Ark Innovation ETF Set To Rebound in 2023?
The Bottom Is In For Meta Platforms, Volatility Is Not Over
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Exxon Mobil Could Gush To New Highs Very Soon 
Closing prices for crude oil, gold and other commodities

Invitae - NVTA Stock Forecast, Price & News

$2.69
+0.28 (+11.62%)
(As of 02/2/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.52
$2.93
50-Day Range
$1.71
$2.97
52-Week Range
$1.67
$12.04
Volume
19.50 million shs
Average Volume
8.94 million shs
Market Capitalization
$653.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.90

Invitae MarketRank™ Forecast

Analyst Rating
Hold
1.67 Rating Score
Upside/​Downside
156.5% Upside
$6.90 Price Target
Short Interest
Healthy
17.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.16
Upright™ Environmental Score
News Sentiment
0.23mentions of Invitae in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$114,644 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.42) to ($1.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.39 out of 5 stars

Medical Sector

282nd out of 1,030 stocks

Medical Laboratories Industry

8th out of 25 stocks

NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

Invitae (NYSE:NVTA) Shares Gap Down to $2.48
Invitae (NYSE:NVTA) Stock Price Up 3.5%
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Analysts Set Invitae Co. (NYSE:NVTA) Target Price at $8.45
The Goldman Sachs Group Lowers Invitae (NYSE:NVTA) to Sell
Invitae Reports Preliminary 2022 Financial Results
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
Is Invitae in Danger of Running Out of Money?
Why Shares of Invitae Rose 11% on Tuesday
Why Invitae Stock Is Crushing It Today
Invitae (NVTA) Q3 2022 Earnings Call Transcript
Is Invitae Stock a Buy Now?
Invitae (NYSE: NVTA) Share Price and News
See More Headlines
Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Company Calendar

Last Earnings
11/08/2022
Today
2/02/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
3,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.90
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+156.5%
Consensus Rating
Hold
Rating Score (0-4)
1.67
Research Coverage
12 Analysts

Profitability

Net Income
$-379,010,000.00
Net Margins
-617.65%
Pretax Margin
-626.73%

Debt

Sales & Book Value

Annual Sales
$460.45 million
Book Value
$13.16 per share

Miscellaneous

Free Float
240,224,000
Market Cap
$653.40 million
Optionable
Optionable
Beta
1.86

Key Executives

  • Kenneth D. Knight
    Chief Executive Officer & Director
  • Roxi Wen
    Chief Financial Officer
  • Robert L. NussbaumRobert L. Nussbaum
    Chief Medical Officer
  • Karthik Suri
    Chief Product & Technology Officer
  • Eric Olivares
    Chief Science Officer













NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last year. There are currently 4 sell ratings and 8 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2023?

12 equities research analysts have issued twelve-month target prices for Invitae's shares. Their NVTA share price forecasts range from $2.00 to $18.00. On average, they anticipate the company's share price to reach $6.90 in the next twelve months. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2023?

Invitae's stock was trading at $1.86 on January 1st, 2023. Since then, NVTA shares have increased by 46.8% and is now trading at $2.73.
View the best growth stocks for 2023 here
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) announced its quarterly earnings results on Tuesday, November, 8th. The medical research company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.17. The medical research company earned $133.54 million during the quarter, compared to the consensus estimate of $132.80 million. Invitae had a negative trailing twelve-month return on equity of 39.04% and a negative net margin of 617.65%.

What guidance has Invitae issued on next quarter's earnings?

Invitae issued an update on its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $122.00 million-$122.00 million, compared to the consensus revenue estimate of $121.46 million.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an IPO on Thursday, February 12th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan served as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.15%), Sumitomo Mitsui Trust Holdings Inc. (7.10%), Bourne Lent Asset Management Inc. (0.08%), Green Alpha Advisors LLC (0.06%), Redwood Wealth Management Group LLC (0.02%) and Zurcher Kantonalbank Zurich Cantonalbank (0.02%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $2.73.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $663.12 million and generates $460.45 million in revenue each year. The medical research company earns $-379,010,000.00 in net income (profit) each year or ($13.84) on an earnings per share basis.

How many employees does Invitae have?

The company employs 3,000 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 2/3/2023 by MarketBeat.com Staff